Overview
Pharmaceutical

TAIKO PHARMACEUTICAL CO.,LTD.

Daiko Yakuhin Co., Ltd. (大幸薬品株式会社) is a Japanese pharmaceutical company best known for its flagship OTC gastrointestinal drug 'Seirogan,' which has over 100 years of brand history and is sold domestically through pharmacies and drugstores as well as exported to Hong Kong, China, Taiwan, and other markets. The company also operates an Infection Control business centered on its proprietary chlorine dioxide technology under the 'Cleverin' brand, targeting consumers, public institutions, hotels, restaurants, healthcare facilities, and other commercial users. A smaller subsidiary business produces wood vinegar-based bath and gardening products as a by-product of its pharmaceutical manufacturing process.

Market Cap
¥13.1B
US$83.7M
EV
¥10.1B
US$64.5M
Stock¥261▼-0.38%
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
14.1
x
LTM EV/EBIT
23.5
x
LTM PER
19.1
x
LTM PBR
1.6
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-32.2%pt
100
Oct 24, 25 – Oct 23, 26StockTOPIX
MC → EV Bridge
13.1BUS$83.7MMarket Cap0.14BUS$0.91M+ Debt2.67BUS$17.0M− Cash0.50BUS$3.19M− Inv. Sec.10.1BUS$64.5MEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
11.3US$72.1M'21/125.04US$32.1M'22/126.12US$39.0M'23/126.29US$40.1M'24/126.40US$40.8M'25/12
EBITDA 5Y (¥B)
-4.01-US$25.5M'21/12-2.34-US$14.9M'22/12-0.30-US$1.92M'23/120.89US$5.64M'24/120.72US$4.62M'25/12
Net Income 5Y (¥B)
-9.59-US$61.2M'21/12-4.90-US$31.2M'22/12-3.61-US$23.0M'23/120.90US$5.73M'24/120.92US$5.89M'25/12
Capital Structure
98%
EquityD/E 0.02xDebt
Liquidity vs Debt 5Y (¥B)▲ Net Cash
CashInv. Sec.Debt
6.81US$43.4M4.77US$30.4M'21/123.64US$23.2M3.81US$24.3M'22/125.72US$36.5M3.25US$20.8M'23/124.99US$31.8M2.03US$12.9M'24/124.26US$27.1M0.82US$5.20M'25/12
Shareholders
Top 10 hold 49.8%
1
PAULWELL HAN (Standing Proxy: Citibank, N.A., Tokyo Branch)
7.76%
2
Takashi SHIBATA
6.66%
3
Hitoshi SHIBATA
6.58%
4
NOMURA SINGAPORE LIMITED CUSTOMER SEGREGATED A/C FJ-1309 (Standing Proxy: Nomura Securities Co., Ltd.)
6.33%
5
The Master Trust Bank of Japan, Ltd. (Trust Account)
6.17%
6
ZONGYI SOLAR POWER (LUXEMBOURG; Standing Proxy: Citibank, N.A., Tokyo Branch)
4.23%
7
Akihiro SHIBATA
3.78%
8
KOWA COMPANY, LTD.
3.00%
9
Minoru SHIBATA
2.66%
10
Earth Corporation
2.61%
Management
6 officers
Hitoshi SHIBATA
Representative Director, Chairman
Apr 1974 Joined IBM Japan, Ltd. May 1977 Joined the Company Dec 1980 Director; Head of President's Office and Head of Computer Division Apr 1986 Director, Executive Vice President Jul 1987 Representative Director, President Jun 2010 Representative Director, Chairman (current)
1951-04-13
Takashi SHIBATA
Representative Director, President
May 1981 Joined Second Department of Surgery, Osaka University Faculty of Medicine Jun 1981 Osaka Prefectural Senri Emergency Medical Center (now Senri Emergency Medical Center, Osaka Saiseikai Senri Hospital) Jul 1982 Surgery Department, Suita Municipal Hospital Jul 1984 Second Department of Surgery, Osaka University Faculty of Medicine Jun 1987 Surgery Department, Osaka Prefectural Center for Adult Diseases (now National Cancer Center Osaka) Oct 1987 Doctor of Medicine, Osaka University Jan 1990 Surgery Department, Toyonaka Municipal Hospital Dec 1995 Chief of Surgery, Toyonaka Municipal Hospital Jul 1998 Head of Surgery, Toyonaka Municipal Hospital Dec 1998 Director of the Company Nov 2004 Director, Executive Vice President Mar 2006 Representative Director, Executive Vice President Jun 2010 Representative Director, President (current)
1956-07-22
Shoji HASHIMOTO
Senior Managing Director
Apr 2000 Registered as attorney-at-law; joined Hasegawa Toshiaki Law Office Apr 2004 Joined Mitsui Yasuda Law Office Dec 2004 Joined Linklaters Law Office (now Linklaters Gaikokuho Kyodo Jigyo Horitsu Jimusho) Apr 2006 Part-time Lecturer, Graduate School of Asia-Pacific Studies, Waseda University Jan 2007 Joined Allen & Gledhill LLP Dec 2007 Joined Linklaters LLP Jun 2008 Joined Linklaters Gaikokuho Kyodo Jigyo Horitsu Jimusho Jun 2009 Joined Atsumi Sogo Law Office, Gaikokuho Kyodo Jigyo (now Atsumi & Sakai Foreign Law Office Joint Enterprise) Dec 2010 Partner, Atsumi Sogo Law Office, Gaikokuho Kyodo Jigyo Mar 2014 Outside Director, GMO Research, Inc. (now GMO Product Platform, Inc.) (current) Apr 2017 External Member, Compliance Committee, Tokyu REIT Management, Inc. (current) Jun 2017 Outside Director, Astmax Co., Ltd. (current) Jun 2020 Outside Director (Audit and Supervisory Committee Member) of the Company Feb 2024 Representative, Hashimoto Sogo Law Office (current) Mar 2024 Senior Managing Director of the Company (current) Principal Concurrent Positions: Representative, Hashimoto Sogo Law Office Outside Director, GMO Product Platform, Inc. Outside Director, Astmax Co., Ltd. External Member, Compliance Committee, Tokyu REIT Management, Inc.
1967-07-14
Toshihide TOMINAGA
Director (Full-time Audit and Supervisory Committee Member)
Apr 1980 Joined Matsushita Electric Industrial Co., Ltd. (now Panasonic Holdings Corporation) Jun 2007 Director (CFO), Panasonic Communications Co., Ltd. (now Panasonic Connect Co., Ltd.) Jan 2014 Representative Director, President, Panasonic Precision Devices Co., Ltd. (now Panasonic Holdings Corporation) Aug 2015 Vice President, Panasonic Automotive & Industrial Systems Europe GmbH (now Panasonic Industry Europe GmbH) Jun 2016 Representative Director, President, Panasonic Device SUNX Co., Ltd. (now Panasonic Industry Co., Ltd.) Jun 2019 Standing Audit & Supervisory Board Member, Panasonic Corporation (now Panasonic Holdings Corporation) Mar 2024 Director (Audit and Supervisory Committee Member) of the Company (current)
1957-08-03
Kento DOI
Director (Audit and Supervisory Committee Member)
May 1982 Joined Nippon Vicks Co., Ltd. (now P&G Japan LLC) Apr 1987 Brand Manager, Procter & Gamble Healthcare K.K. Apr 1992 Marketing Manager, Procter & Gamble Far East, Inc. (now P&G Japan LLC) Feb 1996 Regional Marketing Director, Procter & Gamble China Jul 1999 Global Marketing Director, The Procter & Gamble Company Oct 2001 Marketing Senior Vice President and Executive Officer, Vodafone Japan Co., Ltd. (now SoftBank Corp.) Nov 2004 Japan Representative and Managing Director, Home Entertainment Division, Sony Pictures Entertainment (Japan) Inc. Aug 2007 Representative Director, President, Levi Strauss Japan K.K. Aug 2010 Representative Director, President, Triumph International Japan Ltd. Feb 2018 Representative Director, Office Kento Doi Co., Ltd. (current) Jul 2022 Senior Executive Director, Consulting Division, Tou Co., Ltd. Mar 2024 Director (Audit and Supervisory Committee Member) of the Company (current) Principal Concurrent Positions: Representative Director, Office Kento Doi Co., Ltd.
1957-11-16
Tetsuo MIWA
Director (Audit and Supervisory Committee Member)
Apr 1985 Joined Takeda Pharmaceutical Company Limited Oct 2003 Head, Drug Functionality Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited Aug 2004 Head, Exploratory Research Center, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited Jun 2006 Chief Member, Product Strategy Department, Takeda Pharmaceutical Company Limited Jul 2008 Vice President, Takeda America Holdings, Inc. Apr 2009 Head, CMC Research Center, Takeda Pharmaceutical Company Limited Feb 2012 Visiting Professor, Graduate School of Engineering, Osaka University Nov 2012 Head, Pharmaceutical Division, Takeda Pharmaceutical Company Limited Apr 2015 Head, Global Pharmaceutical Supply, Japan and Asia, Takeda Pharmaceutical Company Limited Aug 2018 Project Advisor, Otsuka Pharmaceutical Co., Ltd. May 2019 Advisor, Otsuka Pharmaceutical Co., Ltd. (current) Aug 2019 Managing Partner, Conant Advisory Group Japan LLC (current) Mar 2024 Director (Audit and Supervisory Committee Member) of the Company (current) Principal Concurrent Positions: Managing Partner, Conant Advisory Group Japan LLC Advisor, Otsuka Pharmaceutical Co., Ltd.
1958-02-06
Large Shareholding Reports
No filings
Disclosures
No disclosures
Primary Source Filings
EDINET
2026-08-13
Semi-Annual Securities Report
Period: Jan 2026 – Dec 2026
TDnet
2026-08-13
Q2 Earnings Flash
FY ending Dec 2026
TDnet
2026-05-14
Q1 Earnings Flash
FY ending Dec 2026
EDINET
2026-03-24
Annual Securities Report
Period: Jan 2025 – Dec 2025
TDnet
2025-11-11
Q3 Earnings Flash
FY ending Dec 2025
EDINET
2025-08-08
Semi-Annual Securities Report
Period: Jan 2025 – Dec 2025
TDnet
2025-05-09
Q1 Earnings Flash
FY ending Dec 2025
EDINET
2025-03-28
Annual Securities Report
Period: Jan 2024 – Dec 2024
EDINET
2024-08-09
Semi-Annual Securities Report
Period: Jan 2024 – Jun 2024
EDINET
2024-05-10
Quarterly Securities Report
Period: Jan 2024 – Mar 2024
EDINET
2024-03-28
Annual Securities Report
Period: Jan 2023 – Dec 2023
EDINET
2023-11-10
Quarterly Securities Report
Period: Jul 2023 – Sep 2023
EDINET
2023-08-10
Quarterly Securities Report
Period: Apr 2023 – Jun 2023
EDINET
2023-05-12
Quarterly Securities Report
Period: Jan 2023 – Mar 2023
EDINET
2023-03-30
Annual Securities Report
Period: Jan 2022 – Dec 2022
EDINET
2022-11-11
Quarterly Securities Report
EDINET
2022-08-12
Quarterly Securities Report
EDINET
2022-05-13
Quarterly Securities Report
EDINET
2022-03-30
Annual Securities Report
EDINET
2021-11-09
Quarterly Securities Report
EDINET
2021-08-06
Quarterly Securities Report
EDINET
2021-05-07
Quarterly Securities Report
EDINET
2021-03-30
Annual Securities Report
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →